Susie Lisa
Senior Vice President of Investor Relations
Great. Good evening, everyone. My name is Susie Lisa, and as the Senior Vice President of Investor Relations at Vertex Pharmaceuticals. I’m really thrilled that you could all be here with us tonight in Houston and for those of you on the line as well joining us for the American Society of Nephrology Kidney Week 2025 and for a broad update on the Vertex Kidney programs.
I’ll run through the agenda briefly. Our CEO, Dr. Reshma Kewalramani will open with an overview of our 3 kidney programs in pivotal development and 1 currently in a proof-of-concept study. Following Reshma’s remarks, Vertex is extremely pleased and grateful to have 3 physician thought leaders here for you tonight to share their views on the RUBY-3, IgAN and pMN data presented earlier this evening, the RAINIER Phase III study of IgAN, of Pove and IgAN, which recently completed full enrollment in record time and the outlook for guidelines in treating patients with serious kidney diseases like IgAN.
First, we have the pleasure of hearing from Dr. James A. Tumlin, Professor of Medicine in Nephrology at Emory University School of Medicine, Director of Research at Georgia Nephrology and President of NephroNet. Dr. Tumlin will provide a recap of his late breaker presentation of the RUBY-3 data in IgAN
Read the full article here
